Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility

Several new multikinase inhibitors have recently been introduced into clinical practice for hepatocellular carcinoma (HCC) therapy. Small increases in survival were reported as well as considerable toxicity. There is thus a need for effective therapies with lower toxicities. We examined whether a co...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Alessandro, Rosalba, Refolo, Maria Grazia, Iacovazzi, Palma Aurelia, Pesole, Pasqua Letizia, Messa, Caterina, Carr, Brian Irving
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627995/
https://www.ncbi.nlm.nih.gov/pubmed/31181647
http://dx.doi.org/10.3390/cancers11060787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627995/
https://www.ncbi.nlm.nih.gov/pubmed/31181647
http://dx.doi.org/10.3390/cancers11060787

Ejemplares similares